■神经营养性酪氨酸受体激酶(NTRK)基因融合是在0.3%的实体瘤中普遍存在的罕见致癌驱动因素。它们在唾液腺癌中最常见(2.6%),甲状腺癌(1.6%),软组织肉瘤(1.5%)。目前,有两种美国食品和药物管理局批准的NTRK基因融合的靶向疗法:larotrectinib,2018年批准,和entrectinib,2019年批准。迄今为止,在学术癌症中心中,酪氨酸受体激酶抑制剂(TRKi)在NTRK阳性实体瘤中的实际使用情况仍在很大程度上未知.
■为了描述人口统计,临床和基因组特征,以及在美国学术癌症中心治疗的NTRK阳性实体瘤患者的测试和治疗模式。
■这是一项在美国学术癌症中心进行的回顾性图表综述研究。本研究包括所有诊断为NTRK融合阳性(NTRK1,NTRK2,NTRK3)实体瘤(任何阶段)并且在2012年1月1日至2023年7月1日期间在参与部位接受癌症治疗的患者。患者人口统计学,临床特征,基因组特征,NTRK测试数据,从电子病历中收集治疗模式,并酌情使用描述性统计进行分析.
■总共,6个中心提供了55例NTRK阳性肿瘤患者的数据。平均年龄为49.3(SD=20.5)岁,51%的患者为女性,大多数是白人(78%)。从癌症诊断到NTRK测试的中位持续时间为85天(IQR=44-978)。在NTRK测试时,64%的患者患有IV期疾病,与癌症诊断时的33%相比。总体队列中流行的癌症类型包括头颈部(15%),甲状腺(15%),大脑(13%),肺(13%),结直肠(11%)。NTRK1融合最常见(45%),其次是NTRK3(40%)和NTRK2(15%)。在所有的治疗中,51%(n=28)的患者接收了TRKi。在TRKi治疗的患者中,71%的人在TRKi开始时患有IV期疾病。从NTRK试验阳性到开始TRKi的中位时间为48天(IQR=9-207)。TRKis通常作为一线(30%)或二线(48%)疗法给予。使用TRKi的中位治疗持续时间为610天(IQR=182-764),所有其他一线治疗的中位治疗持续时间为207.5天(IQR=42-539)。
■这项研究报告了当代现实世界的NTRK测试模式和TRKis在实体瘤中的应用,包括NTRK测试与开始TRKi治疗之间的时间以及TRKi治疗的持续时间。
UNASSIGNED: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare oncogenic drivers prevalent in 0.3% of solid tumors. They are most common in salivary gland cancer (2.6%), thyroid cancer (1.6%), and soft-tissue sarcoma (1.5%). Currently, there are 2 US Food and Drug Administration-approved targeted therapies for NTRK gene fusions: larotrectinib, approved in 2018, and entrectinib, approved in 2019. To date, the real-world uptake of tyrosine receptor kinase inhibitor (TRKi) use for NTRK-positive solid tumors in academic cancer centers remains largely unknown.
UNASSIGNED: To describe the demographics, clinical and genomic characteristics, and testing and treatment patterns of patients with NTRK-positive solid tumors treated at US academic cancer centers.
UNASSIGNED: This was a retrospective chart review
study conducted in academic cancer centers in the United States. All patients diagnosed with an NTRK fusion-positive (NTRK1, NTRK2, NTRK3) solid tumor (any stage) and who received cancer treatment at participating sites between January 1, 2012, and July 1, 2023, were included in this
study. Patient demographics, clinical characteristics, genomic characteristics, NTRK testing data, and treatment patterns were collected from electronic medical records and analyzed using descriptive statistics as appropriate.
UNASSIGNED: In total, 6 centers contributed data for 55 patients with NTRK-positive tumors. The mean age was 49.3 (SD = 20.5) years, 51% patients were female, and the majority were White (78%). The median duration of time from cancer diagnosis to NTRK testing was 85 days (IQR = 44-978). At the time of NTRK testing, 64% of patients had stage IV disease, compared with 33% at cancer diagnosis. Prevalent cancer types in the overall cohort included head and neck (15%), thyroid (15%), brain (13%), lung (13%), and colorectal (11%). NTRK1 fusions were most common (45%), followed by NTRK3 (40%) and NTRK2 (15%). Across all lines of therapy, 51% of patients (n = 28) received a TRKi. Among TRKi-treated patients, 71% had stage IV disease at TRKi initiation. The median time from positive NTRK test to initiation of TRKi was 48 days (IQR = 9-207). TRKis were commonly given as first-line (30%) or second-line (48%) therapies. Median duration of therapy was 610 (IQR = 182-764) days for TRKi use and 207.5 (IQR = 42-539) days for all other first-line therapies.
UNASSIGNED: This
study reports on contemporary real-world NTRK testing patterns and use of TRKis in solid tumors, including time between NTRK testing and initiation of TRKi therapy and duration of TRKi therapy.